# Estrella Immunopharma, Inc.: overview ESLA · Nasdaq · CIK 1844417 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/esla.md) · [Financials](/companies/esla/financials.md) · [Filings](/companies/esla/filings.md) · [Insiders](/companies/esla/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.09)](/filings/0001213900-25-109198.md) | not reported | [(0.06)](/filings/0001213900-26-058063.md) | [(0.15)](/filings/0001213900-26-089215.md) | [(0.13)](/filings/0001213900-25-109198.md) | not reported | [(0.05)](/filings/0001213900-26-058063.md) | [(0.05)](/filings/0001213900-26-089215.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 6-month figure less the 3-month figure; 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 6-month figure less the 3-month figure; 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | [(36.35)](/filings/0001213900-24-082374.md) | [(0.27)](/filings/0001013762-25-002190.md) | [(0.35)](/filings/0001213900-26-029357.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/esla/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $4.1m | 3,975,220 | | Reduced −123,780 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $433.5k | 416,852 | | Added +34,383 | | [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $197.5k | 189,899 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $147.0k | 141,321 | | Reduced −16,164 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $67.5k | 64,921 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $54.1k | 52,033 | | Added +12,143 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $45.0k | 43,252 | | Unchanged | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $40.7k | 39,100 | | Reduced −23,695 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $36.3k | 34,861 | | Added +15,237 | | [US BANCORP \\DE\\](/funds/36104.md) | 2026-06-30 | $20.8k | 20,000 | | Added +3,096 | ## Recent filings [All 256 filings](/companies/esla/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 17:28 ET | [8-K](/filings/0001213900-26-113912.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-113912 | | 2026-09-08 | 17:25 ET | [8-K](/filings/0001213900-26-098123.md) | 3.01 Delisting notice | 0001213900-26-098123 | | 2026-08-21 | 17:00 ET | [8-K](/filings/0001213900-26-092657.md) | 3.01 Delisting notice | 0001213900-26-092657 | | 2026-08-13 | 17:01 ET | [10-Q](/filings/0001213900-26-089215.md) | Quarterly report, period 2026-06-30 | 0001213900-26-089215 | | 2026-06-30 | 17:29 ET | [8-K](/filings/0001213900-26-073847.md) | 5.07 Shareholder vote results | 0001213900-26-073847 | | 2026-05-27 | 17:25 ET | [DEF 14A](/filings/0001140361-26-023012.md) | Proxy statement, period 2026-06-29 | 0001140361-26-023012 | | 2026-05-18 | 21:26 ET | [10-Q](/filings/0001213900-26-058063.md) | Quarterly report, period 2026-03-31 | 0001213900-26-058063 | | 2026-04-30 | 17:27 ET | [10-K/A](/filings/0001213900-26-050433.md) | Annual report, amended, period 2025-12-31 | 0001213900-26-050433 | | 2026-03-18 | 20:53 ET | [10-K](/filings/0001213900-26-029357.md) | Annual report, period 2025-12-31 | 0001213900-26-029357 | | 2026-01-22 | 20:51 ET | [S-1/A](/filings/0001213900-26-006410.md) | Registration statement, amended | 0001213900-26-006410 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-029357.md), filed Mar 18, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1844417 - Tickers: ESLA, ESLAW - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: not reported - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:29 ET. No prices; not investment advice.